The company has an early stage pipeline of novel, multi-cistronic gene therapy products targeting diabetic macular edema (DME), age-related macular degeneration (AMD, both wet and dry forms) and ocular hypertension.
This company has no teams yet
NHS Innovation Accelerator
2 followers
Avalere Health
5 followers
MSD in the UK
5 followers
Oxford Quantum Circuits
7 followers
Lead Exposure Elimination Project
1 follower
SYNLAB UK & Ireland
5 followers
TCG Labs-Soleil
1 follower
GBUK Group
2 followers
Terumo Aortic
3 followers
Symprove Ltd
1 follower
Vantive
11 followers
Oxford Nanopore Technologies
19 followers